- Purpose of This Guideline
- Benefits and Risks of ART
- Rationale for Rapid ART Initiation
- Counseling and Education Before Initiating ART
- Protocol for Rapid ART Initiation
- General Principles in Choosing a Regimen for Rapid ART Initiation
- Special Considerations
- All Recommendations
- All Good Practices
- Guideline Information and Updates
- Purpose of This Guideline
- Available ART Regimens
- General Principles in Choosing an Initial ART Regimen
- General Considerations With Initial ART Regimens
- Specific Factors to Consider and Discuss With Patients
- Special Considerations for Comorbid Conditions
- ART-Initiation Laboratory Testing
- ARV Dose Adjustments for Hepatic or Renal Impairment
- All Recommendations
- Guideline Information and Updates
- Purpose of This Guideline
- Identifying and Managing Virologic Failure
- ART Changes to Address Drug Resistance
- ART Changes for Adverse Effects, Drug-Drug Interactions, or Pregnancy
- ART Changes for Regimen Simplification
- Resumption of ART After a Treatment Interruption
- All Recommendations
- Guideline Information
- Purpose of This Guideline
- Efficacy of CAB/RPV LA
- Benefits, Potential Risks, and Limitations of CAB/RPV LA
- Initiation, Maintenance, and Discontinuation of CAB/RPV LA as ART
- Laboratory Testing and Patient Follow-Up
- Implementing CAB/RPV LA in Clinical Practice
- All Recommendations
- Guideline Information and Updates
- Clinical Guidelines Program Approach to Shared Decision-Making
- NYSDOH HIV Care Provider Definitions
- Use of Dolutegravir in Individuals of Childbearing Capacity
- NYSDOH Health Equity Competencies for Health Care Providers
- Selected Links: Resources for Clinicians
- Selected Links: Resources for Consumers
- All FDA-Approved HIV Medications, With Brand Names and Abbreviations